



## **VIVALDI BIOSCIENCES TO PRESENT UNIVERSAL INFLUENZA VACCINE DATA AT WORLD VACCINE CONGRESS**

FORT COLLINS, Colorado and VIENNA, Austria – March 29, 2023 – Vivaldi Biosciences, a clinical-stage biotechnology company developing nasal spray vaccines for viral respiratory diseases, will present data on its DeltaFLU universal influenza vaccine at the World Vaccine Congress in Washington, DC on April 5.

Thomas Muster, PhD, Chief Scientific Officer of Vivaldi Biosciences, will present data showing broad protection with DeltaFLU universal influenza vaccine against influenza virus type A and B strains. These proof-of-concept data from preclinical challenge studies indicate the potential for DeltaFLU to protect against all influenza strain types causing seasonal and pandemic influenza in humans.

Vivaldi Biosciences is preparing for a Phase 2 clinical challenge study to demonstrate efficacy and the potential for universal protection with DeltaFLU universal influenza vaccine. The randomized, placebo-controlled challenge study will evaluate protection conferred by DeltaFLU in healthy adult volunteers in a controlled setting. Clinical challenge studies can indicate efficacy faster and with a smaller number of subjects than conventional Phase 3 studies.

DeltaFLU is a nasal spray vaccine with a unique mode of action. DeltaFLU rapidly induces interferon and broadly cross-neutralizing mucosal antibodies in the nasal passages, creating a first line of defense at the point of entry of circulating viruses. The self-adjuvanting effect of interferon enhances T- and B-cell activity for a broadly protective systemic immune response, with cross-protective serum antibodies directed to conserved regions of the influenza hemagglutinin antigen.

### **About Vivaldi Biosciences**

Vivaldi Biosciences develops genetically engineered intranasal vaccines for epidemic and pandemic viral respiratory diseases. The company's patented vaccine technology centers on eliminating the influenza NS1 gene to generate self-adjuvanting live attenuated vaccines that are more effective than prior nasal spray vaccines. Vivaldi Biosciences has completed Phase 1 and 2 clinical trials of DeltaFLU vaccine strains, demonstrating broad immunogenicity and safety, including absence of replication and shedding. The company's Delta-19 combination vaccine for Covid-19 and influenza is in preclinical development. Vivaldi Biosciences' Vero-cell based vaccine manufacturing system uses patented advances in production and purification for high yields and reduced costs. Vivaldi Biosciences is a venture-backed company with operations at the Research Innovation Center at Colorado State University, Fort Collins, Colorado, and in Vienna, Austria. NGN Capital LLC is the company's lead investor. Learn more at [www.vivaldibiosciences.com](http://www.vivaldibiosciences.com). Connect with Vivaldi Biosciences on LinkedIn.

### **Contact**

Bill Wick, CEO, Vivaldi Biosciences  
Tel: +1 650-400-8915  
[bill.wick@vivaldibiosciences.com](mailto:bill.wick@vivaldibiosciences.com)

## **Forward-Looking Statements**

*This release contains forward-looking statements relating to Vivaldi Biosciences, which are not historical facts and are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements included in this communication concerning activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements. Forward-looking statements are based on current expectations and projections about future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, the following: the uncertainty of clinical success and of obtaining regulatory approvals, the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, product efficacy or safety concerns resulting in product recalls or regulatory action, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the ability to obtain future funding and to obtain such funding on commercially reasonable terms, the regulatory environment and other risks the Company may identify from time to time in the future. These factors are not necessarily all of the important factors that could cause our actual results, performance or achievements to differ materially from those expressed in or implied by any of our forward-looking statements. These forward-looking statements speak only as of the date of this communication and we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. This press release should not constitute an offer to sell or a solicitation of an offer to buy securities.*